Blautia sp. B2132 Probiotic for IBD Flora Balance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Inflammatory bowel disease (IBD) is characterized by an imbalance in intestinal flora, leading to chronic inflammation and a lack of effective treatments targeting the Lachnospiraceae species, which are typically underrepresented in IBD patients.
Innovation Solution
The application of Blautia sp. B2132 strain, a specific probiotic bacterium, is proposed to regulate intestinal flora and treat IBD. This strain is incorporated into pharmaceutical compositions, food, and healthcare products, with a pharmaceutically effective dose of 10^6 to 10^10 CFU and a suitable carrier such as milk powder or cyclodextrin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional treatment protocols (aminosalicylic acid anti-inflammatory drugs, immunosuppressants, or colectomy) are used to induce or maintain ulcerative colitis remission, then remission can be achieved, but complications gradually increase
Solution Approach 1:
The patent uses probiotics (specifically Lactobacillus, Bifidobacterium, and other beneficial bacteria) as an intermediary to modulate the intestinal microenvironment. These probiotics act as mediators that restore microbial balance, enhance barrier function, and reduce inflammation without the severe side effects of traditional drugs, thereby achieving remission while minimizing complications
Solution Approach 2:
The patent converts the harmful effect of intestinal flora imbalance into a beneficial therapeutic approach by using probiotics to restore microbial diversity. The disrupted microbiota is transformed from a source of inflammation into a therapeutic tool, where beneficial bacteria compete with pathogens and restore homeostasis, reducing complications associated with traditional treatments
2Reliability
If probiotics are used to improve intestinal microenvironment and restore normal flora, then intestinal tract inflammation can be controlled and remission maintained, but the diversity and abundance of specific beneficial bacteria (Lachnospiraceae) remain significantly reduced in IBD patients
Solution Approach 1:
The patent combines multiple probiotic strains including Lactobacillus, Bifidobacterium, and other beneficial bacteria into compound probiotic preparations. This merging of different bacterial species creates a synergistic effect that not only controls inflammation but also restores the abundance of Lachnospiraceae and other underrepresented beneficial bacteria in the intestinal microbiota
Solution Approach 2:
The patent changes the parameter of bacterial diversity and composition by introducing specific probiotic strains that increase the abundance of Lachnospiraceae. Through controlled administration of probiotics, the patent modifies the microbiota profile from a state of reduced diversity to one with restored beneficial bacterial populations, thereby addressing both inflammation control and microbial restoration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Blautia sp. B2132 strain effectively inhibits the growth of harmful intestinal bacteria, improves intestinal flora balance, and demonstrates significant therapeutic potential in preventing and treating IBD, including ulcerative colitis and Crohn's disease, without toxic side effects.
Implementation Method 1
Blautia sp. B2132 strain effectively inhibits the growth of harmful intestinal bacteria, improves intestinal flora balance
Data Source
AI summary
Provided are a Blautia sp. B2132 strain and an application thereof. The Blautia sp. B2132 strain has a deposit number of CGMCC No. 1.5296 and is used for regulating the homeostasis of intestinal flora and for preventing or treating the occurrence of an intestinal disease such as an inflammatory bowel disease.